- Home
- OHI vs RPRX Comparison
OHI vs RPRX Comparison
Compare OHI & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OHI
- RPRX
- Stock Information
- Founded
- OHI 1992
- RPRX 1996
- Country
- OHI United States
- RPRX United States
- Employees
- OHI N/A
- RPRX N/A
- Industry
- OHI Real Estate Investment Trusts
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- OHI Real Estate
- RPRX Health Care
- Exchange
- OHI Nasdaq
- RPRX Nasdaq
- Market Cap
- OHI 10.8B
- RPRX 11.8B
- IPO Year
- OHI N/A
- RPRX 2020
- Fundamental
- Price
- OHI $40.10
- RPRX $26.43
- Analyst Decision
- OHI Buy
- RPRX Strong Buy
- Analyst Count
- OHI 12
- RPRX 6
- Target Price
- OHI $38.18
- RPRX $41.67
- AVG Volume (30 Days)
- OHI 2.0M
- RPRX 3.1M
- Earning Date
- OHI 10-30-2024
- RPRX 11-06-2024
- Dividend Yield
- OHI 6.68%
- RPRX 3.18%
- EPS Growth
- OHI 40.81
- RPRX 518.56
- EPS
- OHI 1.36
- RPRX 2.55
- Revenue
- OHI $1,011,391,000.00
- RPRX $2,266,003,000.00
- Revenue This Year
- OHI N/A
- RPRX $12.38
- Revenue Next Year
- OHI $7.77
- RPRX $11.26
- P/E Ratio
- OHI $29.40
- RPRX $10.35
- Revenue Growth
- OHI 18.25
- RPRX N/A
- 52 Week Low
- OHI $27.53
- RPRX $25.10
- 52 Week High
- OHI $44.42
- RPRX $31.66
- Technical
- Relative Strength Index (RSI)
- OHI 46.73
- RPRX 45.67
- Support Level
- OHI $39.52
- RPRX $25.47
- Resistance Level
- OHI $40.54
- RPRX $26.67
- Average True Range (ATR)
- OHI 0.94
- RPRX 0.64
- MACD
- OHI -0.11
- RPRX 0.05
- Stochastic Oscillator
- OHI 47.28
- RPRX 40.80
About OHI Omega Healthcare Investors Inc.
Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.